TW200607802A - 3-piperidinylisochroman-5-ols as dopamine agonists - Google Patents
3-piperidinylisochroman-5-ols as dopamine agonistsInfo
- Publication number
- TW200607802A TW200607802A TW094113776A TW94113776A TW200607802A TW 200607802 A TW200607802 A TW 200607802A TW 094113776 A TW094113776 A TW 094113776A TW 94113776 A TW94113776 A TW 94113776A TW 200607802 A TW200607802 A TW 200607802A
- Authority
- TW
- Taiwan
- Prior art keywords
- piperidinylisochroman
- ols
- formula
- dopamine agonists
- compounds
- Prior art date
Links
- PEUXHIGWBHZERT-UHFFFAOYSA-N 3-piperidin-1-yl-3,4-dihydro-1h-isochromen-5-ol Chemical class C1C=2C(O)=CC=CC=2COC1N1CCCCC1 PEUXHIGWBHZERT-UHFFFAOYSA-N 0.000 title 1
- 229940052760 dopamine agonists Drugs 0.000 title 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 230000003935 attention Effects 0.000 abstract 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229960003638 dopamine Drugs 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56655704P | 2004-04-29 | 2004-04-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200607802A true TW200607802A (en) | 2006-03-01 |
Family
ID=34967397
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW094113776A TW200607802A (en) | 2004-04-29 | 2005-04-29 | 3-piperidinylisochroman-5-ols as dopamine agonists |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7919508B2 (enExample) |
| EP (1) | EP1749001B1 (enExample) |
| JP (1) | JP4685861B2 (enExample) |
| AR (1) | AR050245A1 (enExample) |
| AT (1) | ATE459618T1 (enExample) |
| DE (1) | DE602005019719D1 (enExample) |
| DK (1) | DK1749001T3 (enExample) |
| ES (1) | ES2342083T3 (enExample) |
| PT (1) | PT1749001E (enExample) |
| TW (1) | TW200607802A (enExample) |
| WO (1) | WO2005111025A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110087687A (zh) * | 2016-07-29 | 2019-08-02 | 赛诺维信制药公司 | 化合物、组合物及其用途 |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014339136C1 (en) * | 2013-10-22 | 2019-10-31 | Chiesi Farmaceutici S.P.A. | Process for the preparation of a PDE4 inhibitor |
| CA2946990A1 (en) * | 2014-04-28 | 2015-11-05 | Pfizer Inc. | Heterocyclic compounds and their use as dopamine d1 ligands |
| EA035544B1 (ru) * | 2014-10-08 | 2020-07-03 | Юсб Байофарма Спрл | Производные тетрагидроизохинолина |
| SG10202100724UA (en) * | 2016-07-29 | 2021-03-30 | Sunovion Pharmaceuticals Inc | Compounds and compositions and uses thereof |
| AU2017311691B2 (en) | 2016-08-18 | 2021-12-02 | Vidac Pharma Ltd. | Piperazine derivatives, pharmaceutical compositions and methods of use thereof |
| MX2020000523A (es) * | 2017-08-02 | 2020-08-20 | Sunovion Pharmaceuticals Inc | Compuestos de isocromano y usos de los mismos. |
| CN111196781B (zh) * | 2018-11-16 | 2023-07-28 | 湖南中南制药有限责任公司 | 一种改进的制备五氟利多的方法 |
| JP7703449B2 (ja) | 2019-03-14 | 2025-07-07 | スミトモ・ファーマ・アメリカ・インコーポレイテッド | イソクロマニル化合物の塩およびその結晶体、ならびにそれらの製造方法、治療用途および医薬組成物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4963568A (en) * | 1989-05-31 | 1990-10-16 | Abbott Laboratories | Dopamine agonists |
| US4994486A (en) * | 1989-05-31 | 1991-02-19 | Abbott Laboratories | Dopaminergic compounds |
| ES2194303T3 (es) * | 1997-02-07 | 2003-11-16 | Aventis Pharma Inc | Derivados de (4-piperidinil)-1h-2-benzopirano utiles como agentes antipsicoticos. |
| US6004982A (en) * | 1997-09-15 | 1999-12-21 | Hoechst Marion Roussel, Inc. | 4-piperidinyl) H-2-benzopyran derivatives useful as antipsychotic agents |
-
2005
- 2005-04-27 ES ES05740005T patent/ES2342083T3/es not_active Expired - Lifetime
- 2005-04-27 AT AT05740005T patent/ATE459618T1/de active
- 2005-04-27 PT PT05740005T patent/PT1749001E/pt unknown
- 2005-04-27 JP JP2007510941A patent/JP4685861B2/ja not_active Expired - Fee Related
- 2005-04-27 DK DK05740005.3T patent/DK1749001T3/da active
- 2005-04-27 WO PCT/US2005/014487 patent/WO2005111025A1/en not_active Ceased
- 2005-04-27 EP EP05740005A patent/EP1749001B1/en not_active Expired - Lifetime
- 2005-04-27 DE DE602005019719T patent/DE602005019719D1/de not_active Expired - Lifetime
- 2005-04-28 AR ARP050101668A patent/AR050245A1/es not_active Application Discontinuation
- 2005-04-29 TW TW094113776A patent/TW200607802A/zh unknown
-
2006
- 2006-10-24 US US11/552,169 patent/US7919508B2/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110087687A (zh) * | 2016-07-29 | 2019-08-02 | 赛诺维信制药公司 | 化合物、组合物及其用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2342083T3 (es) | 2010-07-01 |
| JP4685861B2 (ja) | 2011-05-18 |
| ATE459618T1 (de) | 2010-03-15 |
| US20070099955A1 (en) | 2007-05-03 |
| AR050245A1 (es) | 2006-10-11 |
| JP2007535548A (ja) | 2007-12-06 |
| DK1749001T3 (da) | 2010-06-28 |
| WO2005111025A1 (en) | 2005-11-24 |
| US7919508B2 (en) | 2011-04-05 |
| PT1749001E (pt) | 2010-05-31 |
| EP1749001B1 (en) | 2010-03-03 |
| EP1749001A1 (en) | 2007-02-07 |
| DE602005019719D1 (de) | 2010-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200806299A (en) | Treatment of pain | |
| GEP20022676B (en) | 4-Phenyl-Pyridine Derivatives, Method for Their Production and Their Use for Treatment of Disorders Caused by Antagonist of NK-1 Receptors | |
| ATE375341T1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
| IL176110A0 (en) | Azabicyclic heterocycles as cannabinoid receptor modulators | |
| TW200637828A (en) | Novel cis-imidazolines | |
| GEP20084551B (en) | 4-phenylamino-quinazolin-6-yl-amides | |
| YU71901A (sh) | NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA | |
| IL176107A0 (en) | Azabicyclic heterocycles as cannabinoid receptor modulators | |
| MX340965B (es) | Combinaciones para el tratamiento de enfermedades que involucran la proliferacion celular. | |
| UA85708C2 (ru) | Лекарственные комбинации, содержащие бензоксазины, для лечения заболеваний дыхательных путей | |
| TW200504034A (en) | Therapeutic agents | |
| TW200635903A (en) | Therapeutic agents | |
| UA96777C2 (ru) | Фенилпропионамидные соединения и их применение как опиоидных агонистов | |
| PL1678172T3 (pl) | Związki azabicykliczne do łagodzenia bólu oraz leczenia zaburzeń centralnego układu nerwowego | |
| MX2010004312A (es) | Derivados de 1,3,4-tiadiazol espiro-condensados para inhibir la actividad de quinesina de la proteina de quinesina del huso. | |
| TWI367751B (en) | Pharmaceutical composition comprising rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction | |
| UA85707C2 (ru) | Бензоксазины для лечения заболеваний дыхательных путей | |
| SI1765816T1 (sl) | Substituirani 1-propiolil-piperazini z afiniteto za MGLUR5 receptor za zdravljenje bolečih stanj | |
| TW200633986A (en) | Therapeutic agents | |
| TW200639159A (en) | Treatment of pain | |
| MXPA05010020A (es) | Derivados de oxamida. | |
| IL195632A0 (en) | Substituted carboxamides | |
| WO2006058016A3 (en) | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin | |
| TW200631956A (en) | Azabenzoxazoles for the treatment of CNS disorders | |
| PL2155736T3 (pl) | Nowy związek, karbamoiloksyaryloalkanoiloarylopiperazyna, kompozycje farmaceutyczne zawierające ten związek oraz sposoby leczenia bólu, stanu lękowego i depresji przez podawanie tego związku |